1. ALLA AKTIER
  2. NYHETER
  3. LIDDS

LIDDS

Nyheter LIDDS Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

LIDDS presents at investor events

UPPSALA, SWEDEN - LIDDS AB (publ) announces today that the company’s CEO Anders Månsson will participate at Stora Aktiedagen and BioStock Life Science Fall Summit.

LIDDS’ CEO Anders Månsson presents the company at Stora Aktiedagen in Stockholm on 28 November at 08.00. Stora Aktiedagen is arranged by Aktiespararna and is webcasted live and on demand on Aktiespararna’s youtube channel and aktiespararna.se.

LIDDS’ CEO Anders Månsson also participates in BioStock Life Science Fall Summit in Lund where he presents the company on 30 November at 09.05.

Both presentations will be available on the company website www.liddspharma.com after the events.

For additional information, please contact

Anders Månsson, CEO
Phone: +46 (0)70 860 47 38
E-mail: anders.mansson@liddspharma.com
 
Jenni Björnulfson, CFO
Phone: +46 (0)70 855 38 05
E-mail: jenni.bjornulfson@liddspharma.com

LIDDS’ Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and solve problems within many indication areas. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage development, and projects about to enter clinical phase. The company is listed on Nasdaq First North Growth Market.

Attachments

LIDDS presents at investor events

Datum 2022-11-24, kl 14:45
Källa MFN
Bifogade filer
LIDDS presents at investor events